AIM AIM ImmunoTech Inc.: institutional ownership and insider trading
19 funds reported holding $345K of AIM ImmunoTech Inc. in their latest 13F filings; in Q2 2026 funds net bought $276K, with 4 new positions and 4 funds selling out; over the last 12 months insiders bought $18.6K and sold $0 on the open market; over its last four quarters it reported revenue of $95.0K and net income of −$14.3M.
AIM revenue and earnings
- Quarter ended Jun 30, 2026: revenue $26.0K, net income −$3.79M, EPS -0.43
- Quarter ended Mar 31, 2026: revenue $22.0K, net income −$3.02M, EPS -0.69
- Quarter ended Dec 31, 2025: revenue $21.0K, net income −$4.18M, EPS -6.46
- Quarter ended Sep 30, 2025: revenue $26.0K, net income −$3.28M, EPS 1.57
Largest institutional holders of AIM
- JANE STREET GROUP, LLC — $229K
- Virtu Financial LLC — $35.0K
- VANGUARD GROUP INC — $19.8K
- MORGAN STANLEY (MS, MS-PA, MS-PE, MS-PF, MS-PI, MS-PK, MS-PL, MS-PO, MS-PP, MS-PQ) — $14.4K
- GEODE CAPITAL MANAGEMENT, LLC — $13.1K
- GOLDMAN SACHS GROUP INC (GS, GSCE, GS-PA, GS-PC, GS-PD) — $9.21K
- UBS Group AG (UBS) — $8.22K
- SUSQUEHANNA INTERNATIONAL GROUP, LLP — $6.21K
- VANGUARD FIDUCIARY TRUST CO — $4.98K
- Ground Swell Capital, LLC — $3.47K
Recent AIM insider trades
- Oct 22, 2026: Equels Thomas K bought 31,250 shares ($5.09K)
- Sep 17, 2026: Equels Thomas K bought 24,000 shares ($5.04K)
- Sep 16, 2026: Equels Thomas K bought 11,000 shares ($2.31K)
- Sep 15, 2026: Equels Thomas K bought 22,000 shares ($4.84K)
5%+ owners
- Orca Capital AG: 9.9% (Schedule 13G, filed May 12, 2026)